C. Aires

Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: A review

M. Duran, R. Wanders, R. Wanders, 2008, Journal of Inherited Metabolic Disease.

New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA.

I. T. de Almeida, R. Wanders, M. Durán, 2011, Journal of hepatology.

Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10‐2474

P. Soares-da-Silva, C. Aires, M. Bonifácio, 2020, British journal of pharmacology.

Studies on the extra-mitochondrial CoA -ester formation of valproic and Delta4 -valproic acids.

I. T. de Almeida, R. Wanders, M. Durán, 2007, Biochimica et biophysica acta.

Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis.

I. T. de Almeida, R. Wanders, M. Durán, 2010, Biochemical pharmacology.

Pyruvate uptake is inhibited by valproic acid and metabolites in mitochondrial membranes

I. T. de Almeida, M. Durán, G. Soveral, 2008, FEBS letters.

Valproic acid metabolites inhibit dihydrolipoyl dehydrogenase activity leading to impaired 2-oxoglutarate-driven oxidative phosphorylation.

I. T. de Almeida, R. Wanders, M. Durán, 2007, Biochimica et biophysica acta.

Pyruvate uptake is inhibited by valproic acid and metabolites in mitochondrial membranes

I. T. de Almeida, M. Durán, G. Soveral, 2008, FEBS letters.